Health Condition 1: C029- Malignant neoplasm of tongue, unspecified
Conditions
Interventions
Intervention1: Nivolumab 40mg: Nivolumab 40mg iv every 3 weekly will be given for 3 cycles along with the NACT
Intervention2: CTRT: Patients who respond to chemoimmunotherapy,will be considered eligib
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Stage III/ Stage IV (AJCC 8th edition) Squamous Cell Carcinoma of Tongue 2. Upfront Resectable (as deemed by a DMG surgeon) 3. N stage: N0-N2c (AJCC 8th edition) 4. Requiring Major Glossectomy (Type IV/ Type V-Ansarin Classification) (22) 5. With CPS score more than equal to 1 on Bx (IHC)
Exclusion criteria
Exclusion criteria: 1.N3a/N3b tumors (AJCC 8th edition) 2.Unresectable at baseline 3.Recurrent Tumors 4.Having Received other cancer-directed treatment 5.Verrucous lesions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy and safety of neoadjuvant chemoimmunotherapy and chemoradiation for tongue preservation in patients requiring a major glossectomyTimepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify a subgroup of Indian oral cavity cancer patients who have a good response to Neoadjuvant chemoimmunotherapyTimepoint: 2.5 years | — |
Countries
India
Contacts
Public ContactDr Shwetabh Sinha
TATA MEMORIAL HOSPITAL
Outcome results
None listed